Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + CRT in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06143748Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Mar 2024; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06143748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143748.